Jumpcode Genomics Inc.
- UEI
- KJG3YNKKEKW6
- CAGE
- 89QJ3
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $25,300 |
Contract awards
Grant awards
Similar vendors
About the company
Jumpcode Genomics Inc. is a for-profit corporate entity based in San Diego, California, registered in the System for Award Management (SAM) since February 2019, with registration valid through January 2026. The company specializes in advanced genomic technologies, focusing on CRISPR-based solutions and next-generation sequencing (NGS) diagnostic capabilities. Their core competencies include developing custom primers, designing genomic depletion technologies, and creating innovative molecular biology tools that enhance genetic testing and research methodologies.
In terms of federal contract awards, Jumpcode Genomics Inc. has secured contracts from multiple federal agencies, including the Department of Agriculture Agricultural Research Service and the Department of Health and Human Services. Their contract work involves providing specialized services such as DEPLETEX custom primers and custom design services for agricultural research, as well as developing CRISPR-powered NGS-based agnostic diagnostic capabilities. The contracts have been competitively awarded with no specific set-aside designations, with contract values ranging from $25,300 to $740,000. These contracts demonstrate the company's expertise in creating advanced molecular biology solutions for government research and diagnostic purposes.
Regarding federal grant awards, Jumpcode Genomics Inc. has received grants from agencies like the National Human Genome Research Institute, focusing on cutting-edge genomic research. Their grant work includes developing CRISPR-based depletion technologies to resolve pseudogene contamination in next-generation sequencing, with a specific focus on improving newborn screening (NBS) clinical tests. One notable grant project aims to enhance the sensitivity and specificity of detecting disease-causing genetic mutations by computationally designing CRISPR guide RNAs and optimizing depletion protocols. Another grant involves targeted depletion of cattle host transcripts for high-resolution metatranscriptomics analysis of tissue-embedded microbial communities. These grants, valued around $383,748, highlight the company's innovative approach to advancing precision medicine and genomic research methodologies.
Quick answers
Is Jumpcode Genomics Inc. registered in SAM.gov?
Jumpcode Genomics Inc.'s SAM.gov registration expired on January 13, 2026.
How much has Jumpcode Genomics Inc. received in federal contracts?
Federal contracts obligated $25,300 to Jumpcode Genomics Inc. in fiscal years 2023 through 2027.
What is Jumpcode Genomics Inc.'s most recent federal award?
Jumpcode Genomics Inc.'s most recent federal grant award is Crispr-based depletion method for resolving pseudogene contamination in next generation sequencing (NGS) based… (R43HG014080), from National Human Genome Research Institute (NIH), on March 3, 2025.
On GovTribe
See Jumpcode Genomics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors